HS-IT101 Injection in the Treatment of Advanced Melanoma
Status:
ENROLLING_BY_INVITATION
Trial end date:
2027-05-30
Target enrollment:
Participant gender:
Summary
Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced melanoma.